• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 5:06:12 PM ET
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCEL alert in real time by email
    SC 13G/A 1 d130914dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Atreca, Inc.

    (Name of Issuer)

    Class A Common Stock, par value $0.0001

    (Title of Class of Securities)

    04965G109

    (CUSIP Number)

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


          Page 2 of 9
    CUSIP No. 04965G109      

     

     

      1    

      Name of reporting persons.

     

      Boxer Capital, LLC

      2  

      Check the appropriate box if a member of a group. (See instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      Sole voting power.

     

      -0-

       6   

      Shared voting power.

     

      2,202,333

       7   

      Sole dispositive power.

     

      -0-

       8   

      Shared dispositive power.

     

      2,202,333

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      2,202,333

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      7.3%*

    12  

      Type of reporting person

     

      OO

     

    *

    Based on 29,991,270 shares of Class A Common Stock outstanding, as of November 12, 2020 as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2020.


    CUSIP No. 04965G109    Page 3 of 9

     

      1    

      Name of reporting persons.

     

      Boxer Asset Management Inc.

      2  

      Check the appropriate box if a member of a group. (See instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      Bahamas

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      Sole voting power.

     

      -0-

       6   

      Shared voting power.

     

      2,202,333

       7   

      Sole dispositive power.

     

      -0-

       8   

      Shared dispositive power.

     

      2,202,333

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      2,202,333

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      7.3%*

    12  

      Type of reporting person

     

      CO

     

    *

    Based on 29,991,270 shares of Class A Common Stock outstanding, as of November 12, 2020 as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2020.


          Page 4 of 9
    CUSIP No. 04965G109      

     

     

      1    

      Name of reporting persons.

     

      Joe Lewis

      2  

      Check the appropriate box if a member of a group. (See instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      United Kingdom

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      Sole voting power.

     

      -0-

       6   

      Shared voting power.

     

      2,202,333

       7   

      Sole dispositive power.

     

      -0-

       8   

      Shared dispositive power.

     

      2,202,333

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      2,202,333

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      7.3%*

    12  

      Type of reporting person

     

      IN

     

    *

    Based on 29,991,270 shares of Class A Common Stock outstanding, as of November 12, 2020 as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2020.


          Page 5 of 9
    CUSIP No. 04965G109      

     

     

      1    

      Name of reporting persons.

     

      MVA Investors, LLC

      2  

      Check the appropriate box if a member of a group. (See instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      Sole voting power.

     

      -0-

       6   

      Shared voting power.

     

      5,675

       7   

      Sole dispositive power.

     

      -0-

       8   

      Shared dispositive power.

     

      5,675

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      5,675

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      0.0%*

    12  

      Type of reporting person

     

      OO

     

    *

    Based on 29,991,270 shares of Class A Common Stock outstanding, as of November 12, 2020 as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2020.


          Page 6 of 9
    CUSIP No. 04965G109      

     

     

      1    

      Name of reporting persons.

     

      Aaron I. Davis

      2  

      Check the appropriate box if a member of a group. (See instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      Sole voting power.

     

      -0-

       6   

      Shared voting power.

     

      5,675

       7   

      Sole dispositive power.

     

      -0-

       8   

      Shared dispositive power.

     

      5,675

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      5,675

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      0.0%*

    12  

      Type of reporting person

     

      IN

     

    *

    Based on 29,991,270 shares of Class A Common Stock outstanding, as of November 12, 2020 as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2020.


    Page 7 of 9

     

    This Amendment No. 2 (“Amendment No. 2”) amends and supplements the statement on Schedule 13G initially filed on July 1, 2019 (the “Original Filing”) by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”), MVA Investors, LLC (“MVA Investors”) and Joe Lewis, as amended by Amendment No. 1 filed on February 14, 2020 by Boxer Capital, Boxer Management, MVA Investors, Joe Lewis and Aaron Davis (collectively, the “Reporting Persons”). The Original Filing, as amended, remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 2. Capitalized terms used and not defined in this Amendment No. 2 have the meanings set forth in the Original Filing, as amended.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    Boxer Capital, Boxer Management and Joe Lewis beneficially own 2,202,333 shares of Common Stock. MVA Investors and Aaron Davis beneficially own 5,675 shares of Common Stock. The Reporting Persons beneficially own, in the aggregate, 2,208,008 shares of Common Stock.

     

      (b)

    Percent of class:

    The number of shares of Common Stock beneficially owned by Boxer Capital, Boxer Management and Joe Lewis represent 7.3% of the Issuer’s outstanding Common Stock. The number of shares of Common Stock beneficially owned by MVA Investors and Aaron Davis represent 0.0% of the Issuer’s outstanding Common Stock. The number of shares of Common Stock beneficially owned by the Reporting Persons represent, in the aggregate, 7.4% of the Issuer’s outstanding Common Stock. All percentages are based on 29,991,270 shares of Common Stock outstanding, as of November 12, 2020 as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2020.

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:

    None of the Reporting Persons has sole power to vote or to direct the vote of any shares of Common Stock.

     

      (ii)

    Shared power to vote or to direct the vote:

    Boxer Capital, Boxer Asset Management and Joe Lewis have shared power to vote or to direct the vote of the 2,202,333 shares of Common Stock they beneficially own. MVA Investors and Aaron Davis have shared power to vote or to direct the vote of the 5,675 shares of Common Stock they beneficially own.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    None of the Reporting Persons has sole power to vote or to direct the vote of any shares of Common Stock.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    Boxer Capital, Boxer Asset Management and Joe Lewis have shared power to dispose or to direct the disposition of the 2,202,333 shares of Common Stock they beneficially own. MVA Investors and Aaron Davis have shared power to dispose or to direct the disposition of the 5,675 shares of Common Stock they beneficially own.


    Page 8 of 9

     

    Item 10. Certification.

    (c) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Exhibits

     

      1

    Joint Filing Agreement, dated February 14, 2020, among the Reporting Persons, incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons on February 14, 2020.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    February 16, 2021

     

    BOXER CAPITAL, LLC
    By:  

    /s/ Aaron I. Davis

    Name: Aaron I. Davis
    Title: Chief Executive Officer
    BOXER ASSET MANAGEMENT INC.
    By:  

    /s/ Jason Callender

    Name: Jason Callender
    Title: Director
    JOSEPH C. LEWIS

    /s/ Joseph C. Lewis

    Joseph C. Lewis, Individually
    MVA INVESTORS, LLC
    By:  

    /s/ Aaron I. Davis

    Name: Aaron I. Davis
    Title: Authorized Signatory
    AARON I. DAVIS

    /s/ Aaron I. Davis

    Aaron I. Davis, Individually
    Get the next $BCEL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BCEL

    DatePrice TargetRatingAnalyst
    3/4/2022$17.00 → $14.00Buy
    Stifel
    More analyst ratings

    $BCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunome to Acquire Antibody-Related Assets and Materials from Atreca

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (NASDAQ:BCEL) to acquire a collection of antibody-related assets and materials. "We believe that novel and underexplored targets will drive the next generation of transformative ADCs. These antibody-related assets will expand our toolbox, complementing our existing programs as we advance our mission of developing innovative treatments for cancer patients," stated Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome. Under the terms of the ass

      12/26/23 8:30:00 AM ET
      $BCEL
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome

      CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. ("Atreca") (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into a definitive asset purchase agreement with Immunome, Inc. (NASDAQ:IMNM) to sell a collection of antibody-related assets and materials. Under the terms of the agreement, Immunome would pay Atreca up to $12.5 million, consisting of a $5.5 million upfront payment and up to $7.0 million in clinical development milestones. "We are pleased to announce this asset purchase agreement with Immunome, a com

      12/26/23 8:30:00 AM ET
      $BCEL
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

      SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives. "Since our founding, Atreca has leveraged a unique discovery platform to identify numerous antibodies binding no

      11/14/23 4:30:08 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/17/24 7:36:28 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Financials

    Live finance-specific insights

    See more
    • Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update

      ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year APN-497444 and APN-346958 programs advancing with nomination of clinical candidates expected in 2023 Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EDT SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogati

      3/29/23 4:05:12 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023

      SAN CARLOS, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will host a conference call and webcast on Wednesday, March 29, 2023, at 4:30 p.m. EDT to report financial results and provide an update on its discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101. To access the conference call by telephone, please use this link to register and receive the dial-in numbers and unique PIN to access the call. To acc

      3/23/23 5:00:36 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Announces Expansion of Preclinical Pipeline

      Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced a licensing agreement with Zymeworks Inc. (Zymeworks) (NYSE:ZYME) to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the C

      4/5/22 4:01:00 PM ET
      $BCEL
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Orwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/17/24 7:36:28 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Serafini Tito sold $1,455 worth of shares (20,788 units at $0.07), decreasing direct ownership by 32% to 43,636 units (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/3/24 9:50:22 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orwin John A sold $8,597 worth of shares (22,951 units at $0.37), decreasing direct ownership by 23% to 77,541 units (SEC Form 4)

      4 - Atreca, Inc. (0001532346) (Issuer)

      4/3/24 9:37:17 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel reiterated coverage on Atreca with a new price target

      Stifel reiterated coverage of Atreca with a rating of Buy and set a new price target of $14.00 from $17.00 previously

      3/4/22 7:37:56 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird resumed coverage on Atreca with a new price target

      Robert W. Baird resumed coverage of Atreca with a rating of Outperform and set a new price target of $27.00 from $30.00 previously

      6/4/21 7:01:08 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Atreca with a new price target

      Jefferies initiated coverage of Atreca with a rating of Buy and set a new price target of $30.00

      2/8/21 5:57:56 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    SEC Filings

    See more
    • SEC Form DEFM14A filed by Atreca Inc.

      DEFM14A - Atreca, Inc. (0001532346) (Filer)

      4/22/24 9:21:58 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PREM14A filed by Atreca Inc.

      PREM14A - Atreca, Inc. (0001532346) (Filer)

      4/11/24 4:52:06 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Atreca Inc.

      15-12G - Atreca, Inc. (0001532346) (Filer)

      4/1/24 4:31:35 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Atreca Appoints Philippe Bishop, MD as Chief Medical Officer

      SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately. "Dr. Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATRC-101. As an accomplished executive and medical oncologist with extensive experience in cancer drug development, his leadership and expertise will be invaluable as we continue to advance ATRC-101, a

      1/9/23 8:30:54 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

      - Industry Veterans Expand Company's Business and Operations Functions Cellino Biotech, Inc., an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer. Together, these leaders will support the company's growth and further enhance its ability to build an integrated technology platform for the development and scaling of regenerative medicines. "We are delighted to welcome Abhi and Paulette, who bring invaluable expertise in advanced technology development and business to

      6/27/22 8:00:00 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

      SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer. "Stephen is an exceptional scientific leader with particular experience in the development of weaponized antibody-based therapeutics, and we are excited to welcome him to the Atreca team," said John Orwin, Chief Executive Officer of Atreca. "Our discovery platform has proven to be highly productive in generating promising tumor-sele

      6/16/22 4:05:22 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Atreca Inc.

      SC 13G - Atreca, Inc. (0001532346) (Subject)

      1/10/24 4:52:48 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atreca Inc. (Amendment)

      SC 13G/A - Atreca, Inc. (0001532346) (Subject)

      12/7/22 10:24:32 AM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atreca Inc. (Amendment)

      SC 13G/A - Atreca, Inc. (0001532346) (Subject)

      2/14/22 4:47:03 PM ET
      $BCEL
      Biotechnology: Pharmaceutical Preparations
      Health Care